Project Grant R44TR006344
Award Date 8/1/26
Completion Date 5/31/28
Dollars Obligated $931K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded Nabgen Inc. $312,461 on August 1, 2026, under the NCATS program (CFDA 93.350) to develop an engineered, long-acting protein M derived from mycoplasma for blocking alloantibodies in patients receiving protein replacement therapy. Nabgen is engineering protein M to neutralize inhibitory antibodies that develop in response to biological drugs, particularly in treatments for lysosomal storage...
- The National Institute of Allergy and Infectious Diseases awarded Partillion Bioscience Corp $306,865 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanovial-based technologies for accelerated monoclonal antibody discovery and characterization. Partillion will engineer novel nanovial formulations to enable streptavidin-antigen complexes as detection agents, increasing the multiplexing capacity of single-cell antibody screening assays. The...
- The National Center for Advancing Translational Sciences, part of the National Institutes of Health, awarded University of California Irvine $413,771 on June 1, 2026, under the NCATS program (CFDA 93.350) to develop an in vitro method for rapid antibody evolution based on functional selection rather than antigen-binding strength alone. The project, titled "Accelerated Antibody Evolution Under Functional Selection," will create allosteric modulators for G protein-coupled receptors using...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees Of The Stevens Institute Of Technology $192,765 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds development of a machine learning-guided coarse-grained modeling framework to predict antibody behavior in high-concentration formulations for subcutaneous drug delivery. The research integrates small-angle X-ray scattering (SAXS), viscosity, and aggregation...
- The National Institute of Biomedical Imaging and Bioengineering awarded New York University $186,504 on July 3, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop continuous flow manufacturing processes for antibody-loaded nanoparticles as a non-opioid therapy for oral cancer pain. The award funds development of the Biologics Sequential Nanoprecipitation (BIOSNAP) process, a novel manufacturing method designed...
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded Onca Bio, Inc. $697,696 on September 15, 2025, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop segmented in vitro translation (SIVT) technology for expanding peptide library diversity in mRNA display applications. Onca Bio will apply SIVT to overcome a key limitation in current mRNA display macrocycle libraries, which are constrained by fixed residues at two...
- The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health awarded $322,184 to Delaqua Pharmaceuticals, Inc. on August 5, 2026, under the NCATS program (CFDA 93.350) to develop a non-PEG polymeric micelle platform technology for enhanced drug solubilization and oral bioavailability. Delaqua is developing a stealth, hyper-loaded polymeric micelle approach for drugs co-administered with P-glycoprotein (PGP) inhibitors. The platform targets the dual...
- The National Institutes of Health National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $430,521 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop, optimize, and validate novel monoclonal antibody tools for exploring altered glycosylation in tumor cells. The recipient will develop and validate TACA-specific (tumor-associated carbohydrate antigen-specific) monoclonal antibodies targeting dysregulated glycan expression on cancer cell...
- The National Institute on Aging, a division of the Department of Health and Human Services National Institutes of Health, awarded Advantage Therapeutics, Inc. $3.749 million on September 20, 2025, under the Aging Research program (CFDA 93.866) to perform IND-enabling studies on a small-molecule immunomodulating compound for Alzheimer's disease. The recipient will conduct preclinical and IND-enabling studies on a disease-modifying therapeutic designed to reduce brain inflammation and restore...
- The National Institute of Allergy and Infectious Diseases awarded Triangle Biotechnology, Inc. one million dollars on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to commercialize nanodroplet technology for improved microbial lysis and DNA extraction from difficult-to-lyse samples. Triangle Biotechnology is developing SnapLyse, a proprietary cavitation-enhancing nanodroplet reagent paired with low-power sonication for efficient, high-throughput, and...